UNSPSC 51373426: Chlorpheniramine/codeine/phenylpropanolamine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.

UNSPSC 51373426 Chlorpheniramine/codeine/phenylpropanolamine is a Commodity code covering branded and generic pharmaceutical products, though recent state and local activity tagged under this code shows a mismatch between the specific drug formulation and the actual procurements being solicited. The two most recent opportunities involve naloxone and safe drug deactivation systems (Seminole County, Florida) and a broad cooperative purchasing agreement for generic multi-source pharmaceuticals and OTC products (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP, administered by the Minnesota Department of Administration). The issuing bodies include county health departments and multi-state cooperative purchasing entities serving state and local government facilities. Work under this code involves supply and delivery of pharmaceutical inventory to public health agencies and healthcare facilities, with vendors managing logistics, compliance with FDA and Drug Supply Chain Security Act requirements, and quality assurance across distribution networks.

The code shows recent activity in Florida and Minnesota. Seminole County issued an Invitation for Bid (IFB 60459723LAS, response deadline Jul 26, 2023) for annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida, requiring vendors to cover all shipping costs and maintain workers' compensation, commercial general liability, and professional liability insurance. MMCAP issued a multi-state Request for Proposal (S1070000015802, response deadline Mar 26, 2026) to establish contracts for generic pharmaceuticals and OTC products distributed across state and local facilities in Minnesota and Oregon, requiring compliance with current Good Manufacturing Practices and Drug Supply Chain Security Act standards, relationships with at least two of three authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health, Morris & Dickson Co.), and submission of detailed product information including NDC codes, with evaluation weighted 75 percent on price competitiveness and contract performance penalties ranging from $200 to $1,500 per violation.